Our mission: to make complex medical testing simple and accessible wherever and whenever needed.
Orbis Diagnostics believes everyone should be empowered to understand their true health status, irrespective of who they are and where they live. High quality, accessible diagnostics enable individuals within society to make life-changing decisions with confidence. Established in 2016, Orbis brings together a proven team of world-leading researchers, backed by New Zealand’s largest early stage deep-tech investor, Pacific Channel.
Orbis has developed a ‘lab on a disk’ testing platform that uses its microfluidic platform technology to miniaturise and automate accurate lab testing for use at points of need. Originally designed for the cowshed, the first product to run on this platform was able to accurately quantify progesterone in milk for heat detection, to inform the timing of artificial insemination. With the outbreak of COVID-19, Orbis recognised how the unique features of our system could help re-enable safe travel amidst a pandemic and quickly pivoted the company to develop a quantitative immunity test for COVID-19.
The Orbis team are currently collaborating with the University of Otago and Christchurch Heart Institute to obtain 150 pre-COVID-19 blood samples to validate the specificity of its QIC Test relative to established medical laboratory systems.
Following this successful stage 1 testing, Orbis will seek to partner with organisations and, using the Arca Prototype, test vaccinated individuals to confirm there is a robust correlation between antibody level and vaccination status within a specific population.
From Cows to COVID
The COVID-19 pandemic clarified the need for a scalable quantitative antibody test to verify immunity at the point of need, and Orbis’ system was perfectly suited. The team pivoted to developing a COVID-19 immunity test, exploiting the advantages of an automated system designed for a non-lab environment.